Dry Powder Inhalers (DPI)

Access the delivery technology best suited to the needs of your development programme, including unit-dose and multi-unit dose DPIs, pMDIs and smart nebulisers, suitable for home or hospital applications.

Dry Powder Inhalers:
Options include proprietary unit- and multi-unit dose platforms, as w...

With expertise in powder and liquid formulations for small molecules and biologics, as well as a broad portfolio of proprietary device and formulation technologies, we can help you overcome the challenges of inhaled formulation development.

Dry Powder Formulation
Advanced po...

With extensive, state-of-the-art analytical testing facilities and equipment, our expert teams are able to develop and validate the methodologies required to characterise inhaled delivery platforms, especially DPI, pMDI and nebulised products.

To ensure seamless support for your development...

In addition to extensive development manufacturing facilities, Vectura has GMP manufacturing facilities for dry powder inhalers, pMDI and nebuliser medical devices as well as further capability to handle biological molecules. 

Our GMP manufacturing facilities and equipment are relevant-to-comme...

Our formulation, device and development services are supported by our medical, regulatory, device vigilance and pharmacovigilance teams to safeguard your programme and ensure the smoothest path to product approval.

Our in-house team can support with:

Global regulatory development strategy...

Our state-of-the-art breath-actuated nebulisers with guided inhalation have been developed to improve lung delivery for inhaled drugs, with the aim of achieving better clinical outcomes and/or shortened treatment times.

FOX® nebuliser: handheld system that delivers high...

From one-off studies and specialist techniques through to full development services, our inhalation services can support your programme through all stages of clinical development and get your product ready for commercial manufacturing.

We understand different customers may require different t...

Explore the series of Learning Labs at CPHI North America in which thought leaders at our exhibitors showcase their extensive knowledge on all areas of the pharma supply chain, offering industry insights across drug manufacturing, outsourcing, pharma ingredients, drug delivery and packaging.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. The future commercial success of any new inhaled medicine relies largely on the correct combination of formulation and device technology chosen for its delivery. This presentation benefits any drug developer considering an inhaled programme and aims to answer the following questions: How are development targets and success criteria set for inhaled products? What are the key factors influencing inhaled delivery platform selection? How can phase-appropriate device selection accelerate an inhaled development programme?

IHL-216A may make sports safer and reduce the morbidity and mortality rates of people suffering serious head traumas

Vectura inhaled formulation, device and development services

The enhancements will include installing the lever-operated multi-dose inhaler device used in Hikma’s generic Advair product, which the FDA recently approved

Vectura Dry Powder Inhaler (DPI) services and capabilities

The expansion will enable the CDMO to widen the nature of inhaled drug development projects it can undertake for customers

Strategies to accelerate inhaled drug development including technology platform selection.

Exploring the many factors which contribute to the success of pMDI, DPI and nebuliser development programmes

The future commercial success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology chosen for its delivery. This presentation will benefit any drug developer considering an inhaled programme and aims to answer the following questions: How are development targets and success criteria set for inhaled products? What are the key factors influencing inhaled delivery platform selection? How can phase-appropriate device selection accelerate an inhaled development programme? This session was originally broadcast live as part of CPHI North America 2021

Download this free webcast where Dr Sandy Munro, SVP Pharmaceutical Development, discusses strategies to progress inhaled products quickly to clinical stages of development.

Interested in the critical success factors for an inhaled development programme? Download this article which discusses inhaled delivery platform selection and strategies to accelerate development timelines and reduce risk.

This article discusses how delivery technology can help customers develop existing drugs for inhaled use, as well as highlighting the key challenges and opportunities faced during inhaled product development.

Download a summary of Vectura's services and capabilities